CDD-0102
| CDD-0102 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
CDD-0102 is an investigational drug currently under development for the treatment of neurological disorders. It is being studied for its potential effects on neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Mechanism of Action[edit]
CDD-0102 is believed to function as a neuroprotective agent, potentially modulating pathways involved in neuronal survival and synaptic plasticity. The exact mechanism of action is still under investigation, but preclinical studies suggest that CDD-0102 may influence neurotransmitter systems and reduce oxidative stress in the brain.
Pharmacokinetics[edit]
The pharmacokinetic profile of CDD-0102 is characterized by its absorption, distribution, metabolism, and excretion (ADME) properties. Preliminary studies indicate that CDD-0102 has a moderate bioavailability and is primarily metabolized in the liver. The elimination half-life of CDD-0102 is approximately 12 hours, allowing for potential once-daily dosing.
Clinical Trials[edit]
CDD-0102 is currently in Phase II clinical trials. Early results have shown promise in improving cognitive function in patients with mild to moderate Alzheimer's disease. Further studies are ongoing to evaluate its efficacy and safety in larger populations and across different stages of neurodegenerative diseases.
Potential Side Effects[edit]
As with any investigational drug, CDD-0102 may have side effects. Commonly reported adverse effects in clinical trials include nausea, headache, and dizziness. Long-term safety data are still being collected.
Research and Development[edit]
CDD-0102 was developed by a collaboration between academic institutions and pharmaceutical companies. The research is funded by grants from various health organizations and aims to address the unmet needs in treating neurodegenerative disorders.
Also see[edit]
